Cue Biopharma, Inc. (CUE)

2.4500 -0.0400 (-1.61%) At close: 04:00PM EDT

Cue Biopharma, Inc.

21 Erie Street
Cambridge, MA 02139
United States
617 949 2680
https://www.cuebiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 57

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Daniel R. Passeri J.D., M.Sc., MSc.	CEO & Director	774.7k	N/A	1961
Dr. Anish Suri Ph.D.	Pres & Chief Scientific Officer	598.24k	N/A	1974
Ms. Kerri-Ann Millar	Chief Financial Officer	496.56k	N/A	1970
Dr. Ronald D. Seidel III, Ph.D.	Co-Founder	N/A	N/A	1976
Dr. Rodolfo J. Chaparro	Co-Founder & Sr. Advisor	N/A	N/A	1973
Dr. Steven C. Almo	Co-Founder and Chairman of Scientific & Clinical Advisory Board	N/A	N/A	1961
George B. Zavoico Ph.D.	VP of Investor Relations & Corp. Devel.	N/A	N/A	N/A
Mr. Colin G. Sandercock J.D., MSE	Sr. VP, Gen. Counsel & Sec.	N/A	N/A	1957
Dr. Kenneth J. Pienta M.D.	Acting Chief Medical Officer	N/A	N/A	1960
Dr. Matteo Levisetti M.D.	Sr. VP of Clinical Devel.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cue Biopharma, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.